In November 2015, the Board at UNITAID approved the expansion of MPP’s mandate to cover hepatitis C and tuberculosis.
Hepatitis C is a liver disease caused by the Hepatitis C virus (HCV). According to WHO, between 130 and 150 million people worldwide are estimated to have the virus and approximately 500’000 people die each year of hepatitis C-related diseases. The vast majority of people affected by hepatitis C reside in low- and middle-income countries (LMICs).
New direct-acting antivirals (DAA) that are effective across all major HCV strains can cure millions. Approximately 95% of people infected with HCV worldwide are not receiving treatment.
The MPP will seek to license new and pipeline pan-genotypic DAAs for generic manufacture. The foundation will work with generic partners to speed development and distribution of new HCV treatments that can eliminate the virus in a short course of oral therapy in regions with a high HCV burden.